Multicenter phase 1 study of micvotabart pelidotin monotherapy in previously treated recurrent/metastatic head and neck squamous cell carcinoma

Recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) previously treated with platinum-based chemotherapy and anti-PD-1 therapy lacks standard of care treatment options and remains a high unmet need. Micvotabart pelidotin (MICVO) is an antibody-drug conjugate targeting extradomain-B of fibronectin, a non-cellular structural protein in the tumor extracellular matrix. A multicenter phase 1 study, presented today at the EORTC-NCI-AACR Symposium in Barcelona (Spain) evaluated MICVO for R/M HNSCC previously treated with at least platinum and anti-PD-(L)1. Patients received MICVO intravenously 5.4 mg/kg every three weeks (dose capped at 432 mg for males ≥ 80 kg and 378 for females >70 kg). Among 35 enrolled patients, 33 were response-evaluable. The confirmed objective response rate was 36%, including one complete response, and the disease control rate was 94%. The median progression-free survival was 6.2 months (95% CI 4.8-8.8) and the 12-months overall survival probabilty was 79% (58-90) with median overall survival not reached. Clinical benefit was observed across HPV status and prior treatment subgroups. Among 12 confirmed responders, 9 (75%) achieved response by week 6, and 10 (83%) had > 50% tumor reduction from baseline. Grade ≥ 3 treatment-related adverse events reported in at least two patients included peripheral sensory (8.6%) and motor (8.6%) neuropathy, AST increase (5.7%), GGT increase (5.7%), hyponatremia (5.7%), lymphocyte count decrease (5.7%), and neutrophil count decrease (5.7%). There were no deaths due to TRAEs. The authors conclude that MICVO addresses an unmet need in previously treated HNSCC and demonstrates promising HPV-agnostic activity and a manageable safety profile.